BioSpecifics Technologies Corp. is a profitable, commercial-stage biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is approved for marketing as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. for the treatment of adult Dupuytren's contracture patients with up to two palpable cords in the same palm and for Peyronie's disease in men with a palpable plaque and a curvature of 30 degrees or greater at the start of therapy. XIAFLEX is also approved in Canada & Australia for Dupuytren's contracture and XIAPEX® (the EU tradename for CCH) is approved in the EU for both Dupuytren's contracture and Peyronie's disease.
As of January 29, 2015, BioSpecifics' strategic partner, Auxilium Pharmaceuticals, Inc. (Auxilium) was acquired by Endo International plc (Endo). XIAFLEX is now being marketed by Endo's specialty pharmaceuticals business unit in the U.S. for Dupuytren's contracture and Peyronie's disease and Endo is also managing the research and development of CCH for their licensed indications. Ex-U.S partnerships include Actelion Pharmaceuticals Ltd. in Canada, Australia, Brazil and Mexico, Asahi Kasei Pharma Corporation in Japan and Swedish Orphan Biovitrum AB in 71 Eurasian and African countries.